316 related articles for article (PubMed ID: 25759025)
21. Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.
Ge Z; Zhou X; Gu Y; Han Q; Li J; Chen B; Ge Q; Dovat E; Payne JL; Sun T; Song C; Dovat S
Oncotarget; 2017 Jan; 8(5):8022-8034. PubMed ID: 28030830
[TBL] [Abstract][Full Text] [Related]
22. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
Rickert RC
Nat Rev Immunol; 2013 Aug; 13(8):578-91. PubMed ID: 23883968
[TBL] [Abstract][Full Text] [Related]
23. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
Swaminathan S; Huang C; Geng H; Chen Z; Harvey R; Kang H; Ng C; Titz B; Hurtz C; Sadiyah MF; Nowak D; Thoennissen GB; Rand V; Graeber TG; Koeffler HP; Carroll WL; Willman CL; Hall AG; Igarashi K; Melnick A; Müschen M
Nat Med; 2013 Aug; 19(8):1014-22. PubMed ID: 23852341
[TBL] [Abstract][Full Text] [Related]
24. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
25. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.
Gioia R; Leroy C; Drullion C; Lagarde V; Etienne G; Dulucq S; Lippert E; Roche S; Mahon FX; Pasquet JM
Blood; 2011 Aug; 118(8):2211-21. PubMed ID: 21730355
[TBL] [Abstract][Full Text] [Related]
26. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
[TBL] [Abstract][Full Text] [Related]
27. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
Gioia R; Trégoat C; Dumas PY; Lagarde V; Prouzet-Mauléon V; Desplat V; Sirvent A; Praloran V; Lippert E; Villacreces A; Leconet W; Robert B; Vigon I; Roche S; Mahon FX; Pasquet JM
J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
[TBL] [Abstract][Full Text] [Related]
28. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Munzert G; Kirchner D; Ottmann O; Bergmann L; Schmid RM
Leuk Lymphoma; 2004 Jun; 45(6):1181-4. PubMed ID: 15359998
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
30. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
31. Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kanwar VS; Witthuhn B; Campana D; Ihle JN
Blood; 1996 Jun; 87(11):4911-2. PubMed ID: 8639867
[No Abstract] [Full Text] [Related]
32. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.
Swaminathan S; Duy C; Müschen M
Trends Immunol; 2014 Mar; 35(3):131-7. PubMed ID: 24332591
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain.
Yankee TM; Keshvara LM; Sawasdikosol S; Harrison ML; Geahlen RL
J Immunol; 1999 Dec; 163(11):5827-35. PubMed ID: 10570266
[TBL] [Abstract][Full Text] [Related]
34. Pre-B-cell Receptor Signaling Is a Therapeutic Target in Pre-B ALL.
Cancer Discov; 2015 May; 5(5):OF15. PubMed ID: 25790981
[No Abstract] [Full Text] [Related]
35. BCL6 expression correlates with the t(1;19) translocation in B-lymphoblastic leukemia.
Deucher AM; Qi Z; Yu J; George TI; Etzell JE
Am J Clin Pathol; 2015 Apr; 143(4):547-57. PubMed ID: 25780007
[TBL] [Abstract][Full Text] [Related]
36. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
Chen L; Monti S; Juszczynski P; Ouyang J; Chapuy B; Neuberg D; Doench JG; Bogusz AM; Habermann TM; Dogan A; Witzig TE; Kutok JL; Rodig SJ; Golub T; Shipp MA
Cancer Cell; 2013 Jun; 23(6):826-38. PubMed ID: 23764004
[TBL] [Abstract][Full Text] [Related]
37. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.
Gold MR; Scheid MP; Santos L; Dang-Lawson M; Roth RA; Matsuuchi L; Duronio V; Krebs DL
J Immunol; 1999 Aug; 163(4):1894-905. PubMed ID: 10438924
[TBL] [Abstract][Full Text] [Related]
38. ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
Chiaretti S; Guarini A; De Propris MS; Tavolaro S; Intoppa S; Vitale A; Iacobelli S; Elia L; Ariola C; Ritz J; Foà R
Blood; 2006 Jan; 107(1):197-204. PubMed ID: 16160012
[TBL] [Abstract][Full Text] [Related]
39. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.
Rubbi L; Titz B; Brown L; Galvan E; Komisopoulou E; Chen SS; Low T; Tahmasian M; Skaggs B; Müschen M; Pellegrini M; Graeber TG
Sci Signal; 2011 Mar; 4(166):ra18. PubMed ID: 21447799
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
